• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Chief Financial Officer Lorber Timothy J.

    8/12/25 9:22:09 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SHPH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Lorber Timothy J.

    (Last) (First) (Middle)
    C/O SHUTTLE PHARMACEUTICALS HOLDINGS
    401 PROFESSIONAL DRIVE, SUITE 260

    (Street)
    GAITHERSBURG MD 20879

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Shuttle Pharmaceuticals Holdings, Inc. [ SHPH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    08/08/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Unit (1) 08/08/2025 A 29,240 (2) (2) Common Stock 29,240 $0 29,240 D
    Restricted Stock Unit (1) 08/08/2025 A 24,854 (3) (3) Common Stock 24,854 $0 24,854 D
    Explanation of Responses:
    1. Each Restricted Stock Unit ("RSU"s) represents the contingent right to receive one share of common stock.
    2. One-third of these RSUs will vest on each of 08/08/2026, 08/08/2027 and 08/08/2028.
    3. These RSUs will vest on 02/08/2026.
    /s/ Timothy J Lorber 08/12/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SHPH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SHPH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SHPH
    SEC Filings

    View All

    Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

    5/27/26 9:00:14 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by Shuttle Pharmaceuticals Holdings Inc.

    D - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

    5/15/26 4:45:23 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Shuttle Pharmaceuticals Holdings Inc.

    10-Q - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)

    5/15/26 4:31:42 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SHPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Shuttle Pharmaceuticals and United Dogecoin Announce Purchase Order for up to 3,000 ElphaPex Dogecoin and Litecoin Mining Rigs

    Initial Mining Fleet Targeted for Deployment Within 60 Days of Receipt; To Mine DOGE and LTC and Accumulate Mined Coins as Long-Term Treasury AssetsGaithersburg, Maryland--(Newsfile Corp. - May 14, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ:SHPH) ("Shuttle" or the "Company") today announced the closing (the "Closing") of its previously announced merger with United Dogecoin Inc. ("United Dogecoin"), and the confirmation of a purchase order granting the Company the option to purchase up to 3,000 next-generation ElphaPex Scrypt mining rigs ("Mining Rigs") for use in the Company's Dogecoin (DOGE) and Litecoin (LTC) merge-mining operations. As previously reported on Shuttle's Current R

    5/14/26 4:05:00 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    E.F. Hutton & Co. Serves as Exclusive M&A Advisor and Placement Agent on Completed Shuttle Pharmaceuticals–United Dogecoin Merger to Create the Largest Public Dogecoin Miner

    NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. ("E.F. Hutton"), a leading investment banking and financial advisory firm, today announced it served as exclusive M&A advisor and placement agent in connection with the successful closing of Shuttle Pharmaceuticals Holdings, Inc.'s (NASDAQ:SHPH) acquisition of United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining company driven by industry experts. The transaction, completed pursuant to a definitive merger agreement, resulted in United Dogecoin merging into a wholly owned subsidiary of Shuttle Pharmaceuticals, creating one of the largest publicly traded Dogecoin mining platforms. In connection with the mer

    5/7/26 2:02:34 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shuttle Merges with United Dogecoin to Become the World's Largest Public Dogecoin Miner

    The combination and related financing is expected to result in the largest publicly listed Dogecoin mining company based on percentage of the global hashrateGaithersburg, Maryland--(Newsfile Corp. - April 30, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ:SHPH) ("Shuttle") has entered into a definitive merger agreement to acquire United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining company driven by industry experts. United Dogecoin will be merged into a wholly owned subsidiary of Shuttle. The merger is supported by a $11 million concurrent Private Investment in Public Equity ("PIPE") financing expected to close on May 4, 2026. United Dogecoin's competitive adv

    4/30/26 4:05:00 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SHPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Trasolini Ryan

    3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

    6/1/26 7:11:22 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Liang Yuying

    3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

    1/12/26 4:15:20 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Liriano Angel claimed no ownership of stock in the company (SEC Form 3)

    3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)

    10/29/25 2:05:48 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SHPH
    Leadership Updates

    Live Leadership Updates

    View All

    Shuttle Pharmaceuticals Acquires AI Health Platform

    Rockville, Maryland--(Newsfile Corp. - November 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle" or the "Company") today announced that it has closed the acquisition of the assets and liabilities of 1542770 B.C. Ltd. d/b/a Molecule.ai ("Molecule"), a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies.Under the terms of the agreement, 1563868 B.C. Ltd., a wholly owned subsidiary of Shuttle, acquired substantially all of Molecule's assets and liabilities for a total purchase price of $8 million, payable in a combination of cash and shares of Shuttle common stock, plus an additional contingent $2 million, pay

    11/21/25 9:30:00 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

    GAITHERSBURG, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of George Scorsis as the Chairman of the Board of Directors. Mr. Scorsis has served as director of the Company since February 2025. Mr. Scorsis has over 25 years of experience leading companies in highly regulated industries to rapid growth, including alcohol, energy drinks, and Biotech. From October 2015 to July 2017, Mr. Scorsis worked as President at Mettrum Heal

    6/4/25 4:01:00 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

    GAITHERSBURG, Md., March 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of Christopher Cooper as interim Co-Chief Executive Officer focused on enhancing the Company's capital markets and business capabilities. Dr. Anatoly Dritschilo, Chairman of the Company's Board of Directors, will continue in his role as Co-CEO overseeing the Company's scientific and clinical trial activities. "I am excited to welcome Christopher Cooper as Co-CEO of

    3/12/25 6:20:00 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SHPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Shuttle Pharmaceuticals Holdings Inc. (Amendment)

    SC 13G/A - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)

    10/17/23 6:57:47 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Shuttle Pharmaceuticals Holdings Inc.

    SC 13G - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)

    5/30/23 5:30:57 PM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care